Graft-versus-host disease in children after hematopoietic cell transplantation: potential clinical utility of biomarkers

International Journal of Hematologic Oncology Pub Date : 2015-06-05 DOI:10.2217/IJH.15.8

S. Paczesny

引用次数: 5

Abstract

Biomarkers may improve diagnosis and prognosis, monitoring of response to treatment, allowing for treatment that are customized to the patients, and overall leading to reduce healthcare costs. In the near future, biomarkers will be included in all clinical trials and decisions for a personalized medicine. The biomarker field

查看原文本刊更多论文

儿童造血细胞移植后的移植物抗宿主病:生物标志物的潜在临床应用

生物标志物可以改善诊断和预后，监测对治疗的反应，允许为患者定制治疗，并总体上降低医疗保健成本。在不久的将来，生物标志物将被纳入所有的临床试验和个性化医疗决策中。生物标志物领域

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hematologic Oncology

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.